Firefly Neuroscience corrects press release, acquires Evoke Neuroscience for $6 million, expands assets

From GlobeNewswire: 2025-05-05 21:00:00

Firefly Neuroscience has corrected a press release, announcing its acquisition of Evoke Neuroscience. Terms of the purchase include $6 million, with half in cash and half in Firefly’s common stock. Evoke’s investors may receive a $500,000 earn-out in Firefly’s stock. The acquisition expands Firefly’s assets, including >180,000 brain scans, 27 patents, and >60 commercial users. The acquisition is a major step towards building a proprietary model of the human brain. Firefly aims to revolutionize brain health outcomes for patients with neurological disorders using its BNA™ technology.

The acquisition of Evoke by Firefly represents a strategic move to enhance diagnostic capabilities for brain disorders and diseases. Evoke’s CEO, David Hagedorn Ph.D., sees the transaction as a natural evolution for both companies. Firefly’s CEO, Greg Lipschitz, anticipates rapid growth and innovation, with the goal of building the world’s first EEG/ERP-based foundation model of the human brain. Firefly’s BNA™ technology, developed through AI and machine learning, offers clinicians insights into brain function for accurate diagnosis and treatment planning.



Read more at GlobeNewswire: Correction From Source: Firefly Neuroscience Achieves